← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Angelman Syndrome

MONDO:0007113 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 44 citations openscientist · 63 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Angelman syndrome is caused by loss of functional maternal UBE3A in neurons; the intact paternal UBE3A allele is epigenetically silenced in neurons by the UBE3A antisense transcript (UBE3A-ATS), so neurons depend on the maternal copy.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 96% because paternal UBE3A is epigenetically silenced in neurons by UBE3A-ATS, loss of the maternal allele produces near-absence of UBE3A protein in the brain and the clinical phenotype.
Falcon states the maternal-loss / paternal-silencing imprinting mechanism directly.
openscientist CONCORDANT 96% Angelman syndrome (AS) is caused by the absence of functional maternally derived UBE3A protein, while the paternal UBE3A gene is present but silenced specifically in neurons
OpenScientist asserts the identical maternal-loss / neuron-specific paternal-silencing mechanism.
PMID:32088294

UBE3A encodes an E3 ubiquitin-protein ligase (E6-AP); its loss removes ubiquitin-proteasome-mediated protein degradation in neurons, the molecular starting point of the disease.

UNANIMOUS INTEGRATED
gene_functionpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% UBE3A is an E3 ubiquitin ligase; dysfunction impacts ubiquitin-mediated processes and downstream nuclear/cytoplasmic neuronal function
Falcon identifies UBE3A as an E3 ubiquitin ligase and links dysfunction to ubiquitin-mediated processes.
openscientist CONCORDANT 90% UBE3A mutations result in loss of E3 ubiquitin ligase activity, disrupting ubiquitin-proteasome pathway-mediated protein degradation in neurons
OpenScientist specifies loss of E3 ligase activity and disrupted ubiquitin-proteasome degradation.

AS arises through several molecular classes with characteristic frequencies: maternal 15q11-q13 deletion (~70%), paternal uniparental disomy (~2-7%), imprinting defects (~2-5%), and intragenic UBE3A mutations (~10-15%).

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% with UPD (3–7%), imprinting defects (2–4%), and UBE3A coding mutations (~10%).
Falcon reports the same subtype spectrum and frequency bands (deletion ~70%, UPD 3-7%, imprinting defects 2-4%, UBE3A mutations ~10%).
openscientist CONCORDANT 92% maternal deletions of 15q11-q13 (~70%), paternal uniparental disomy (~5%), imprinting defects (~3%), UBE3A point mutations (~11–15%), and unknown mechanisms (~10–15%).
OpenScientist gives the same class frequencies and additionally quantifies an unknown-mechanism fraction. Minor numeric spread (UPD ~5% vs 3-7%) is overlapping, not conflicting.

A genotype-phenotype severity gradient exists, with maternal-deletion patients the most severely affected, partly because the deletion also removes neighboring genes (GABRB3, GABRA5, GABRG3).

MAJORITY INTEGRATED
genetic_factorprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 92% Deletion patients are the most severely affected across all clinical domains, followed by UPD patients, with imprinting defect and UBE3A mutation patients showing the mildest phenotypes.
OpenScientist states the full across-all-domains severity gradient with deletion worst.
falcon PARTIAL 55% proposed contributors to more severe epilepsy/EEG features relative to non-deletion genotypes.
Falcon supports the deletion-severity direction but frames it specifically for epilepsy/EEG features (via GABA-A subunit hemizygosity) rather than the whole clinical-domain gradient.

Epilepsy affects roughly 80-90% of patients, typically onsets between 1-3 years, is often pharmacoresistant, and is more prevalent with earlier onset in deletion versus non-deletion genotypes.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Intractable epileptic seizures since early childhood with characteristic EEG abnormalities are present in 80-90% patients with AS.
OpenScientist reports the 80-90% prevalence with characteristic EEG and childhood onset.
PMID:32893075
falcon CONCORDANT 85% median seizure onset 24 months (deletion) vs 57 months (non-deletion).
Falcon corroborates the genotype-dependent epilepsy course, quantifying earlier median seizure onset in deletion patients.

Beyond synaptic dysfunction, UBE3A loss produces mitochondrial respiratory-chain dysfunction and oxidative stress, a mechanistic layer that is a candidate druggable target (e.g., MitoQ, idebenone).

MAJORITY LEAD
pathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% AS mice have increased levels of superoxide in area CA1 of the hippocampus that is reduced by MitoQ, a mitochondria-specific antioxidant.
OpenScientist develops the mitochondrial/oxidative-stress mechanism in detail and links it to antioxidant rescue.
PMID:26658871
falcon PARTIAL 50% including dysregulated mTOR signaling, synaptic plasticity deficits, mitochondrial dysfunction, and oxidative stress/ROS, as well as epilepsy linked to GABAergic circuitry dysfunction.
Falcon lists mitochondrial dysfunction and oxidative stress among model-supported abnormalities but does not develop the mechanism or the antioxidant-rescue leads.

The leading disease-modifying strategy is reactivation of the intact but silenced paternal UBE3A allele by suppressing UBE3A-ATS, most notably with antisense oligonucleotides (ASOs), which restore UBE3A and improve phenotypes in models.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Imprinting is central: in neurons the paternal UBE3A allele is silenced by UBE3A-ATS; restoring expression is a main disease-modifying strategy.
Falcon frames paternal-UBE3A unsilencing (via UBE3A-ATS suppression, including ASOs) as the main disease-modifying strategy.
openscientist CONCORDANT 92% ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease
OpenScientist reports the pivotal ASO unsilencing result with protein restoration and cognitive amelioration in the AS mouse model.
PMID:25470045

AS is rare, with prevalence estimates on the order of 1 in 12,000-20,000 (some sources spanning ~1 in 10,000-24,000).

UNANIMOUS INTEGRATED
epidemiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% ~1 in 12,000–20,000 live births (approximately 5–8 per 100,000)
OpenScientist gives the 1 in 12,000-20,000 prevalence and a normalized per-100,000 rate.
falcon CONCORDANT 80% 1 in 10,000–24,000 births
Falcon reports an overlapping prevalence range (1 in 10,000-24,000), consistent with OpenScientist's estimate.

EEG is a defining, sensitive biomarker in AS; quantitative EEG (notably delta-band power) is used both to support diagnosis and to track therapeutic target engagement in trials.

MAJORITY LEAD
diagnosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Quantitative EEG delta power is a leading noninvasive biomarker and can be modeled longitudinally to detect target engagement and treatment effects.
Falcon emphasizes qEEG delta power as a noninvasive biomarker for both diagnosis support and longitudinal therapeutic monitoring.
openscientist PARTIAL 60% Abnormal baseline brain activity in all AS patients
OpenScientist treats EEG as a highly sensitive diagnostic biomarker but does not develop the quantitative delta-power trial-endpoint modeling that Falcon stresses.

Narrative

Overview

Both providers frame Angelman syndrome as a neuron-specific imprinting disorder: loss of functional maternal UBE3A, whose paternal allele is silenced in neurons by the UBE3A-ATS antisense transcript. They converge on the molecular subtype spectrum, the deletion-worst severity gradient, epilepsy as the dominant clinical problem, and paternal-UBE3A unsilencing (especially ASOs) as the transformative therapeutic strategy. Falcon is oriented toward mechanism, EEG biomarkers, and the 2023-2024 unsilencing pipeline; OpenScientist is broader and more clinically comprehensive.

Agreement

Strong agreement on the core biology (maternal UBE3A loss with paternal UBE3A-ATS silencing), UBE3A as an E3 ubiquitin ligase acting through the ubiquitin-proteasome system, the molecular-class frequencies (deletion ~70%, UPD, imprinting defects, intragenic UBE3A mutations), epilepsy in ~80-90% with genotype-dependent onset and prevalence, rarity (~1 in 12,000-20,000), and ASO-mediated paternal-UBE3A reactivation as the leading disease-modifying approach.

Divergence

Divergence is mostly coverage and depth, not conflict. OpenScientist develops the mitochondrial-dysfunction/oxidative-stress mechanism and its antioxidant-rescue leads, the full across-all-domains severity gradient, detailed antiseizure pharmacology, natural history, and differential diagnosis. Falcon foregrounds the quantitative-EEG delta-power biomarker as a longitudinal trial-monitoring tool and the newest unsilencing modalities (small-molecule unsilencers, Cas13). Numeric spreads (UPD ~5% vs 3-7%; prevalence 1 in 12,000-20,000 vs 1 in 10,000-24,000) are overlapping rather than contradictory, so no finding is marked CONTRADICTORY.

Integration

Integrate the imprinting causal mechanism, UBE3A E3-ligase/UPS gene function, the molecular-class frequency spectrum, the deletion-worst genotype-phenotype gradient, the epilepsy phenotype with genotype-dependent onset, the ASO/paternal-UBE3A unsilencing treatment concept, and the rare-prevalence epidemiology into the disorder YAML as curated content.

Not integrated (leads)

The mitochondrial-dysfunction/oxidative-stress druggable pathway and the quantitative-EEG delta-power biomarker are retained as research leads: both are largely model- or trial-derived and warrant primary-literature verification before promotion to curated disease mechanisms.

Cross-provider synthesis comparing falcon (mechanism/biomarker-focused) and openscientist (comprehensive, 15-domain) Angelman syndrome reports. best_matching_text values are verbatim excerpts from the cited report files; no direct contradictions were found, so divergence is coverage/depth plus overlapping numeric spreads. Literature evidence: snippets and ontology terms were intentionally left to the main curation pipeline on the disorder YAML.